1
|
Rayia DMA, Izzularab BM, Harras S, Ghafar MTA, Azzam AR, Harras H, Younis RL, Soliman S, Saad AE. Stem cell biotherapy: A new remedy for Trichinella spiralis-induced inflammatory myopathy. Parasitol Int 2023; 96:102773. [PMID: 37330041 DOI: 10.1016/j.parint.2023.102773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Revised: 06/10/2023] [Accepted: 06/12/2023] [Indexed: 06/19/2023]
Abstract
Trichinella spiralis (T. spiralis)-induced myopathy is an inflammatory myopathy that is difficult to treat unless the parasite is combated in its early intestinal phase before it reaches the muscles. This study aimed to evaluate the effect of local mesenchymal stem cell (MSC) therapy on T. spiralis-induced inflammatory myopathy in rats. Rats were divided into four groups: Group 1 (non-infected non-treated group); Group 2 (infected non-treated group); Group 3 (infected albendazole (ABZ)-treated group); and Group 4 (infected MSC-treated group). Their muscle status was assessed physiologically with the righting reflex and electromyography (EMG), parasitologically with the total muscle larval count, histopathologically with hematoxylin and eosin and Mallory's trichrome stains, as well as immunohistochemically for myogenin as a marker of muscle regeneration. Additionally, serum muscle enzymes creatine kinase (CK) and lactate dehydrogenase (LDH), as well as muscle matrix metalloproteinases MMP1 and MMP9, were assayed. Finally, the immunological response was assessed by measuring the levels of the muscle inflammatory cytokines tumor necrosis factor-alpha (TNF-α), interferon-gamma (INF-γ), and interleukin-4 (IL-4). Our findings revealed that MSC therapy markedly improved muscle EMG and righting reflex, as well as the histopathological appearance of the muscles, reduced inflammatory cellular infiltrates, and increased myogenin immunostaining. It also reduced serum CK and LDH levels, as well as muscle INF-γ, TNF-α, IL-4, MMP1, and MMP9 levels. However, it had no effect on the total muscle larval count. Accordingly, due to its anti-inflammatory properties and muscle-regenerative effect, MSC therapy could be a promising new remedy for T. spiralis-induced myopathy.
Collapse
Affiliation(s)
- Dina Moustafa Abou Rayia
- Medical Parasitology Department, Faulty of Medicine, Tanta University, Egypt; Medical Parasitology Subunit, Microbiology and Immunology Department, Faculty of Medicine, Mutah University, Jordan.
| | - Batoul M Izzularab
- Biochemistry Division, Chemistry Department, Faculty of Science, Damanhour University, Egypt
| | - Samar Harras
- Zoology Department, Faculty of Science, Tanta University, Egypt
| | | | - Asmaa Ramadan Azzam
- Anatomy and Embryology Department, Faculty of Medicine, Tanta University, Egypt
| | - Heba Harras
- Histopathology Department, Faculty of Medicine, Tanta University, Egypt
| | | | - Shaimaa Soliman
- Biostatistics and Public Health Department, Faculty of Medicine, Menoufia University, Egypt
| | - Abeer Ezzat Saad
- Medical Parasitology Department, Faulty of Medicine, Tanta University, Egypt; Medical Parasitology Subunit, Pathology Department, College of Medicine, Jouf University, Sakaka, Saudi Arabia
| |
Collapse
|
2
|
Rayia DA, Othman A, Harras S, Helal D, Dawood L, Soliman S. Bevacizumab: A new take on therapy of muscle phase of Trichinella spiralis infection. Acta Trop 2022; 230:106409. [PMID: 35300938 DOI: 10.1016/j.actatropica.2022.106409] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 02/28/2022] [Accepted: 03/13/2022] [Indexed: 11/01/2022]
Abstract
Trichinellosis is a zoonosis that causes health and economic problems worldwide. The available therapy is far from perfect as the conventional drugs used against Trichinella spiralis (T. spiralis) are active against the intestinal adult parasites but much less active against encapsulated larvae in muscles. Therefore, this work aimed to evaluate the effect of the anti-angiogenic agent, bevacizumab, on the muscle larvae of T. spiralis. For this aim, T. spiralis-infected mice were treated by two different doses of bevacizumab, thereafter larval counts as well as biochemical and pathological changes were evaluated in the muscles. The larval burden was reduced in the muscles of treated mice, denoting a detrimental effect of bevacizumab against encapsulated Trichinella larvae. Moreover, there was marked improvement of muscle inflammation with the treatment, evidenced by reduction of the proinflammatory cytokines (IL-6 and TNF-α) and regression of the inflammatory infiltrates in histological sections. Amelioration of oxidative stress in the muscle was also observed in treated animals with reduction of malondialdehyde and carbonic anhydrase III and increase in superoxide dismutase levels. Finally, the treatment induced downregulation of the expression of VEGF and CD31, denoting suppressed angiogenesis. All these beneficial effects were found to be dose dependent. In conclusion, bevacizumab exhibited anthelmintic, anti-inflammatory, antioxidant, and anti-angiogenic activities against Trichinella during the muscular phase of infection. Therefore, bevacizumab could be considered as a useful adjuvant treatment in the late stages of trichinellosis.
Collapse
|